Your browser doesn't support javascript.
loading
Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication.
Costantini, Manuela; Amoreo, Carla Azzurra; Torregrossa, Liborio; Alì, Greta; Munari, Enrico; Jeronimo, Carmen; Henrique, Rui; Petronilho, Sara; Capitanio, Umberto; Lucianò, Roberta; Suardi, Nazareno; Landi, Maria Teresa; Anceschi, Umberto; Brassetti, Aldo; Fazio, Vito Michele; Gallucci, Michele; Simone, Giuseppe; Sentinelli, Steno; Poeta, Maria Luana.
Afiliação
  • Costantini M; Department of Urology, IRCCS Regina Elena National Cancer Institute-Rome, via Elio Chianesi 53, 00144 Rome, Italy.
  • Amoreo CA; Department of Pathology, IRCCS Regina Elena National Cancer Institute-Rome, via Elio Chianesi 53, 00144 Rome, Italy.
  • Torregrossa L; Department of Surgical, Medical, Molecular Pathology and Critical Area, Anatomic Pathology Section, 56126 Pisa, Italy.
  • Alì G; Department of Surgical, Medical, Molecular Pathology and Critical Area, Anatomic Pathology Section, 56126 Pisa, Italy.
  • Munari E; Department of Pathology, Sacro Cuore Don Calabria, 37024 Negrar, Italy.
  • Jeronimo C; Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
  • Henrique R; Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), 4200-072 Porto, Portugal.
  • Petronilho S; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Capitanio U; Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), 4200-072 Porto, Portugal.
  • Lucianò R; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Suardi N; Cancer Biology and Epigenetics Group, IPO Porto Research Center (GEBC CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto) & Porto Comprehensive Cancer Center (P.CCC), 4200-072 Porto, Portugal.
  • Landi MT; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Anceschi U; Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
  • Brassetti A; Unit of Pathology, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Fazio VM; Unit of Urology, Division of Experimental Oncology, Urological Research Institute (URI), IRCCS Ospedale San Raffaele, 20132 Milan, Italy.
  • Gallucci M; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD 20892, USA.
  • Simone G; Department of Urology, IRCCS Regina Elena National Cancer Institute-Rome, via Elio Chianesi 53, 00144 Rome, Italy.
  • Sentinelli S; Department of Urology, IRCCS Regina Elena National Cancer Institute-Rome, via Elio Chianesi 53, 00144 Rome, Italy.
  • Poeta ML; Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, 00128 Rome, Italy.
Cancers (Basel) ; 12(11)2020 Nov 12.
Article em En | MEDLINE | ID: mdl-33198197
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline Idioma: En Revista: Cancers (Basel) Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália